Latest & greatest articles for Follicle Stimulating Hormone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on Follicle Stimulating Hormone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on Follicle Stimulating Hormone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for Follicle Stimulating Hormone

1. Recombinant luteinizing hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for ovarian stimulation in IVF/ICSI cycles. (PubMed)

Recombinant luteinizing hormone (rLH) and recombinant follicle stimulating hormone (rFSH) for ovarian stimulation in IVF/ICSI cycles. One of the various ovarian stimulation regimens used for in-vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycles is the use of recombinant follicle-stimulating hormone (rFSH) in combination with a gonadotrophin-releasing hormone (GnRH) analogue. GnRH analogues prevent premature luteinizing hormone (LH) surges. Since they deprive the growing (...) follicles of LH, the question arises as to whether supplementation with recombinant LH (rLH) would increase live birth rates. This is an updated Cochrane Review; the original version was published in 2007.To compare the effectiveness and safety of recombinant luteinizing hormone (rLH) combined with recombinant follicle-stimulating hormone (rFSH) for ovarian stimulation compared to rFSH alone in women undergoing in-vitro fertilisation/intracytoplasmic sperm injection (IVF/ICSI).For this update we

2017 Cochrane

2. Reversal of a Blunted Follicle-Stimulating Hormone by Chemotherapy in an Inhibin B–Secreting Adrenocortical Carcinoma (PubMed)

Reversal of a Blunted Follicle-Stimulating Hormone by Chemotherapy in an Inhibin B–Secreting Adrenocortical Carcinoma Adrenocortical carcinomas (ACCs) are revealed in 60% of cases by steroid hypersecretion. Alternatively, it is uncommon to observe a paraneoplastic syndrome due to a peptide oversecretion.We describe a 60-year-old man with a right adrenal mass. Hormonal evaluation showed an ACTH-independent Cushing syndrome. Surprisingly, follicle-stimulating hormone (FSH) levels were (...) suppressed and blunted during gonadotropin-releasing hormone stimulation, despite normal luteinizing hormone levels. Levels of inhibin B, which negatively regulates the pituitary FSH, were very high. Given the atypical hormonal findings, an adrenal mass biopsy was performed, which allowed the diagnosis of an adrenocortical tumor (positive for steroidogenic factor-1 immunostaining). Moreover, an intense α-inhibin subunit immunostaining was observed. Because of the presence of metastases, the patient

Full Text available with Trip Pro

2017 Journal of the Endocrine Society

3. Lack of Specificity of Plasma Concentrations of Inhibin B and Follicle-Stimulating Hormone for Identification of Azoospermic Survivors of Childhood Cancer: A Report From the St Jude Lifetime Cohort Study (PubMed)

Lack of Specificity of Plasma Concentrations of Inhibin B and Follicle-Stimulating Hormone for Identification of Azoospermic Survivors of Childhood Cancer: A Report From the St Jude Lifetime Cohort Study Many male survivors of childhood cancer are at risk for azoospermia. Although both the levels of follicle-stimulating hormone (FSH) and inhibin B are correlated with sperm concentration, their ability to predict azoospermia in survivors of childhood cancer remains uncertain.Semen analysis

Full Text available with Trip Pro

2013 EvidenceUpdates

4. WITHDRAWN: Human menopausal gonadotropin versus recombinant follicle stimulation hormone for ovarian stimulation in assisted reproductive cycles. (PubMed)

WITHDRAWN: Human menopausal gonadotropin versus recombinant follicle stimulation hormone for ovarian stimulation in assisted reproductive cycles. hMG and recombinant FSH, have both been used successfully for controlled ovarian hyperstimulation in in vitro fertilization and embryo transfer (IVF-ET).To compare the effectiveness of hMG with rFSH in ovarian stimulation protocols in IVF or ICSI treatment cycles.We searched the Cochrane Menstrual Disorders and Subfertility Group trials register (...) (searched 3rd Jan 2002), PubMed, MEDLINE, Web of Science (all searched 1985 to May 15 2002), and reference lists of articles. We also contacted manufacturers and researchers in the field.Randomised trials comparing hMG with rFSH for ovarian stimulation in IVF or ICSI treatment for treatment of infertility in normogonadotrophic women.The main outcome measure was ongoing pregnancy/live birth per woman.Secondary outcomes included total gonadotrophin dose used, cancellation, number of oocytes retrieved

2011 Cochrane

5. Expression of follicle-stimulating hormone receptor in tumor blood vessels. (PubMed)

Expression of follicle-stimulating hormone receptor in tumor blood vessels. In adult humans, the follicle-stimulating hormone (FSH) receptor is expressed only in the granulosa cells of the ovary and the Sertoli cells of the testis. It is minimally expressed by the endothelial cells of gonadal blood vessels.We used immunohistochemical and immunoblotting techniques involving four separate FSH-receptor-specific monoclonal antibodies that recognize different FSH receptor epitopes and in situ

2010 NEJM

6. Cost-saving treatment strategies in in vitro fertilization: a combined economic evaluation of two large randomized clinical trials comparing highly purified human menopausal gonadotropin and recombinant follicle-stimulating hormone alpha

Cost-saving treatment strategies in in vitro fertilization: a combined economic evaluation of two large randomized clinical trials comparing highly purified human menopausal gonadotropin and recombinant follicle-stimulating hormone alpha Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2009 NHS Economic Evaluation Database.

7. Cost-effectiveness of recombinant follicle-stimulating hormone (FSH) versus human FSH in intrauterine insemination cycles: a statistical model-derived analysis

Cost-effectiveness of recombinant follicle-stimulating hormone (FSH) versus human FSH in intrauterine insemination cycles: a statistical model-derived analysis Cost-effectiveness of recombinant follicle-stimulating hormone (FSH) versus human FSH in intrauterine insemination cycles: a statistical model-derived analysis Cost-effectiveness of recombinant follicle-stimulating hormone (FSH) versus human FSH in intrauterine insemination cycles: a statistical model-derived analysis Gerli S, Bini V, Di (...) Renzo G C Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study examined the cost-effectiveness of recombinant versus human follicle-stimulating hormone (FSH) in intra-uterine insemination cycles in infertile patients. The authors

2008 NHS Economic Evaluation Database.

8. WITHDRAWN: Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction cycles. (PubMed)

WITHDRAWN: Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction cycles. Until recently, the main source of exogenous follicle stimulating hormone (FSH) for therapeutic use in infertility had been the urine of postmenopausal women. New developments have resulted in the production of FSH in vitro by recombinant DNA technology. The extremely high purity and batch-to-batch consistency of recombinant FSH (rFSH) make it an attractive alternative (...) to urinary FSH (uFSH).To conduct a systematic review and meta-analysis of randomised trials comparing the effectiveness of rFSH with uFSH in ovarian stimulation protocols in in vitro fertilization (IVF) or intra-cytoplasmic sperm injection (ICSI) treatment cycles.Search strategies included on-line searching of the MEDLINE and EMBASE databases from 1985 to 1999, hand searching of bibliographies of relevant publications and reviews and abstracts of scientific meetings, peer consultation and contacting

2007 Cochrane

9. Recombinant versus highly-purified, urinary follicle-stimulating hormone (r-FSH vs. HP-uFSH) in ovulation induction: a prospective, randomized study with cost-minimization analysis

Recombinant versus highly-purified, urinary follicle-stimulating hormone (r-FSH vs. HP-uFSH) in ovulation induction: a prospective, randomized study with cost-minimization analysis Recombinant versus highly-purified, urinary follicle-stimulating hormone (r-FSH vs. HP-uFSH) in ovulation induction: a prospective, randomized study with cost-minimization analysis Recombinant versus highly-purified, urinary follicle-stimulating hormone (r-FSH vs. HP-uFSH) in ovulation induction: a prospective (...) -stimulating hormone (HP-uFSH; Metrodin HP Serono). This intervention was compared with recombinant follicle-stimulating hormone (r-FSH; Gonal-F Serono). Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised the women of couples with a history of infertility of at least one year, and who were undergoing ovulation induction associated with timed intercourse. Setting The study setting was outpatient secondary care. The economic study

2006 NHS Economic Evaluation Database.

10. A Markov model of the cost-effectiveness of human-derived follicle-stimulating hormone (FSH) versus recombinant FSH using comparative clinical trial data

A Markov model of the cost-effectiveness of human-derived follicle-stimulating hormone (FSH) versus recombinant FSH using comparative clinical trial data A Markov model of the cost-effectiveness of human-derived follicle-stimulating hormone (FSH) versus recombinant FSH using comparative clinical trial data A Markov model of the cost-effectiveness of human-derived follicle-stimulating hormone (FSH) versus recombinant FSH using comparative clinical trial data Hatoum H T, Keye W R, Marrs R P (...) , Walton S M, Marshall D C Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of recombinant versus human follicle-stimulating hormone (rFSH versus hFSH) for in vitro fertilisation (IVF) and intra-uterine insemination (IUI). Both

2005 NHS Economic Evaluation Database.

11. Antral follicle count in the prediction of poor ovarian response and pregnancy after in vitro fertilization: a meta-analysis and comparison with basal follicle-stimulating hormone level

Antral follicle count in the prediction of poor ovarian response and pregnancy after in vitro fertilization: a meta-analysis and comparison with basal follicle-stimulating hormone level Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2005 DARE.

12. Recombinant versus urinary follicle-stimulating hormone in intrauterine insemination cycles: a prospective, randomized analysis of cost effectiveness

Recombinant versus urinary follicle-stimulating hormone in intrauterine insemination cycles: a prospective, randomized analysis of cost effectiveness Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2004 NHS Economic Evaluation Database.

13. Using an electrocautery strategy or recombinant follicle stimulating hormone to induce ovulation in polycystic ovary syndrome: randomised controlled trial. (PubMed)

Using an electrocautery strategy or recombinant follicle stimulating hormone to induce ovulation in polycystic ovary syndrome: randomised controlled trial. To compare the effectiveness of an electrocautery strategy with ovulation induction using recombinant follicle stimulating hormone in patients with polycystic ovary syndrome.Randomised controlled trial.Secondary and tertiary hospitals in the Netherlands.168 patients with clomiphene citrate resistant polycystic ovary syndrome: 83 were (...) allocated electrocautery and 85 were allocated recombinant follicle stimulating hormone.Laparoscopic electrocautery of the ovaries followed by clomiphene citrate and recombinant follicle stimulating hormone if anovulation persisted, or induction of ovulation with recombinant follicle stimulating hormone.Ongoing pregnancy within 12 months.. The cumulative rate of ongoing pregnancy after recombinant follicle stimulating hormone was 67%. With only electrocautery it was 34%, which increased to 49% after

Full Text available with Trip Pro

2004 BMJ Controlled trial quality: predicted high

14. Economic evaluation of highly purified menotropin compared with recombinant follicle-stimulating hormone in assisted reproduction

Economic evaluation of highly purified menotropin compared with recombinant follicle-stimulating hormone in assisted reproduction Economic evaluation of highly purified menotropin compared with recombinant follicle-stimulating hormone in assisted reproduction Economic evaluation of highly purified menotropin compared with recombinant follicle-stimulating hormone in assisted reproduction Lloyd A, Kennedy R, Hutchinson J, Sawyer W Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of highly purified menotropin (hMG) and recombinant follicle stimulating hormone (FSH) for ovarian stimulation in patients undergoing in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI). Type of intervention Treatment

2003 NHS Economic Evaluation Database.

15. Analysis of the cost effectiveness of recombinant versus urinary follicle-stimulating hormone in in vitro fertilization/intracytoplasmic sperm injection programs in the United States

Analysis of the cost effectiveness of recombinant versus urinary follicle-stimulating hormone in in vitro fertilization/intracytoplasmic sperm injection programs in the United States Analysis of the cost effectiveness of recombinant versus urinary follicle-stimulating hormone in in vitro fertilization/intracytoplasmic sperm injection programs in the United States Analysis of the cost effectiveness of recombinant versus urinary follicle-stimulating hormone in in vitro fertilization (...) examined in the study were two gonadotropin preparations for patients suffering from infertility and undergoing ovarian stimulation within in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI) programmes: recombinant follicle-stimulating hormone (FSH) and urinary FSH. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population included women undergoing ovarian stimulation during IVF/ICSI. Further inclusion/exclusion criteria

2002 NHS Economic Evaluation Database.

16. Recombinant or urinary follicle-stimulating hormone? A cost-effectiveness analysis derived by particularizing the number needed to treat from a published meta-analysis

Recombinant or urinary follicle-stimulating hormone? A cost-effectiveness analysis derived by particularizing the number needed to treat from a published meta-analysis Recombinant or urinary follicle-stimulating hormone? A cost-effectiveness analysis derived by particularizing the number needed to treat from a published meta-analysis Recombinant or urinary follicle-stimulating hormone? A cost-effectiveness analysis derived by particularizing the number needed to treat from a published meta (...) with recombinant follicle-stimulating hormone (Gonal F, Serono Pharmaceuticals), while the control treatment was superovulation with the highly purified urinary form (Metrodin H, Serono Pharmaceuticals). Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients who had undergone in vitro fertilisation (IVF) and intracytoplasmic sperm injections (ICSI) in which uFSH was used for superovulation. Eight patients were excluded because

2001 NHS Economic Evaluation Database.

17. Ovulation induction with urinary follicle stimulating hormone versus human menopausal gonadotropin for clomiphene-resistant polycystic ovary syndrome. (PubMed)

Ovulation induction with urinary follicle stimulating hormone versus human menopausal gonadotropin for clomiphene-resistant polycystic ovary syndrome. The risks of multiple pregnancy and ovarian hyperstimulation syndrome (OHSS) are increased in women with clomiphene resistance WHO group 2 dysfunction undergoing ovulation induction as well as the risk of spontaneous abortion if conception takes place. Semi-purified preparations of FSH have been developed in an effort to reduce the impact

2000 Cochrane

18. Economic evaluation of a recombinant follicle-stimulating hormone (follitropin beta, Puregon) in infertile women undergoing in vitro fertilisation in Greece

Economic evaluation of a recombinant follicle-stimulating hormone (follitropin beta, Puregon) in infertile women undergoing in vitro fertilisation in Greece Economic evaluation of a recombinant follicle-stimulating hormone (follitropin beta, Puregon) in infertile women undergoing in vitro fertilisation in Greece Economic evaluation of a recombinant follicle-stimulating hormone (follitropin beta, Puregon) in infertile women undergoing in vitro fertilisation in Greece van Loon J, Liaropoulos L (...) , Mousiama T Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Follitropin beta (Puregon (R)), a recombinant follicle-stimulating hormone (rFSH), in infertile women undergoing in vitro fertilisation (IVF). Type of intervention Treatment

2000 NHS Economic Evaluation Database.

19. Follicle-stimulating hormone or human menopausal gonadotropin for ovarian stimulation in in vitro fertilization cycles: a meta-analysis

Follicle-stimulating hormone or human menopausal gonadotropin for ovarian stimulation in in vitro fertilization cycles: a meta-analysis Follicle-stimulating hormone or human menopausal gonadotropin for ovarian stimulation in in vitro fertilization cycles: a meta-analysis Follicle-stimulating hormone or human menopausal gonadotropin for ovarian stimulation in in vitro fertilization cycles: a meta-analysis Agrawal R, Holmes J, Jacobs H S Authors' objectives To re-analyse the results of using (...) follicle-stimulating hormone (FSH) and human menopausal gonadotropin (hMG) during in vitro fertilisation (IVF) treatment, taking into account the different protocols of administration of superactive gonadotropin-releasing hormone (GnRH) analogues (short, long protocol, or no GnRH analog). Searching The authors searched MEDLINE from January 1985 to 1999 using a combination of the keywords 'FSH', 'LH', 'hMG', 'gonadotropins', 'IVF' and 'comparison'. Review articles and abstracts of major scientific

2000 DARE.

20. Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction

Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction Recombinant versus urinary follicle stimulating hormone for ovarian stimulation in assisted reproduction Daya S, Gunby J Authors' objectives To assess the effect of recombinant versus urinary follicle stimulating hormone for ovarian stimulation on pregnancy rates in assisted reproduction (...) in the review Randomised controlled trials (RCTs). Specific interventions included in the review Recombinant follicle stimulating hormone (rFSH) (either follitrophin alpha or follitrophin beta) versus urinary follicle stimulating hormone (uFSH) (either urofollitrophin or urofollitrophin HP). Trials were included whether or not the stimulation protocol included pituitary down-regulation with gonadotropin releasing hormone agonists (GnRHa). Participants included in the review Infertile women undergoing

1999 DARE.